This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Straume, O. Articles by Akslen, L. A. Search for Related Content PubMed PubMed Citation Articles by Straume, O. Articles by Akslen, L. A.

Loss of Nuclear p16 Protein Expression Correlates with Increased Tumor Cell Proliferation (Ki-67) and Poor Prognosis in Patients with Vertical Growth Phase Melanoma¹

Department of Pathology, The Gade Institute, Haukeland University Hospital, N-5021 Bergen, Norway

The CDKN2A (p16^INK4a) cell cycle-inhibitory gene has been associated with development of familial melanoma. Additionally, recent studies indicate that p16 alterations occur frequently in sporadic melanomas. To investigate whether differences in p16 expression are associated with tumor cell proliferation, tumor progression, and patient survival, we examined the immunohistochemical staining of p16 protein in a consecutive series of 202 vertical growth phase melanomas and 68 corresponding metastases and compared the results with Ki-67 expression, p53 expression, clinicopathological variables, and survival data. Forty-five percent of the primary tumors showed absent or minimal nuclear staining for p16 protein. These cases were significantly associated with high Ki-67 expression (P < 0.0001), ulceration (P = 0.001), and vascular invasion (P = 0.03). Further loss of p16 expression was observed in metastatic lesions (77% were negative; P < 0.0001). Absent/minimal nuclear p16 staining significantly predicted poor patient survival (log-rank test, P = 0.0003), with 37% and 67% estimated 10-year survival rates for cases with absent or present p16 expression, respectively. In multivariate analysis, p16 staining was an independent prognostic factor (hazard ratio, 2.5; 95% confidence interval, 1.5–4.2; P = 0.0008), along with p53 expression, Ki-67 expression, anatomical site, Clark’s level of invasion, and vascular invasion. Our findings indicate that loss of nuclear p16 protein expression in vertical growth phase melanomas is associated with increased tumor cell proliferation (Ki-67) and independently predicts decreased patient survival. Cases without p53 expression had improved survival.

This article has been cited by other articles:

				L. A. Fecher, S. D. Cummings, M. J. Keefe, and R. M. Alani Toward a Molecular Classification of Melanoma J. Clin. Oncol., April 20, 2007; 25(12): 1606 - 1620. [Abstract] [Full Text] [PDF]

				H.-Y. Huang, W.-W. Huang, C.-N. Lin, H.-L. Eng, S.-H. Li, C.-F. Li, D. Lu, S.-C. Yu, and C.-Y. Hsiung Immunohistochemical Expression of p16INK4A, Ki-67, and Mcm2 Proteins in Gastrointestinal Stromal Tumors: Prognostic Implications and Correlations with Risk Stratification of NIH Consensus Criteria Ann. Surg. Oncol., December 1, 2006; 13(12): 1633 - 1644. [Abstract] [Full Text] [PDF]

				W. Liu, J. P. Dowling, W. K. Murray, G. A. McArthur, J. F. Thompson, R. Wolfe, and J. W. Kelly Rate of Growth in Melanomas: Characteristics and Associations of Rapidly Growing Melanomas Arch Dermatol, December 1, 2006; 142(12): 1551 - 1558. [Abstract] [Full Text] [PDF]

				I. M. Bachmann, O. J. Halvorsen, K. Collett, I. M. Stefansson, O. Straume, S. A. Haukaas, H. B. Salvesen, A. P. Otte, and L. A. Akslen EZH2 Expression Is Associated With High Proliferation Rate and Aggressive Tumor Subgroups in Cutaneous Melanoma and Cancers of the Endometrium, Prostate, and Breast J. Clin. Oncol., January 10, 2006; 24(2): 268 - 273. [Abstract] [Full Text] [PDF]

				I. M. Bachmann, O. Straume, H. E. Puntervoll, M. B. Kalvenes, and L. A. Akslen Importance of P-Cadherin, {beta}-Catenin, and Wnt5a/Frizzled for Progression of Melanocytic Tumors and Prognosis in Cutaneous Melanoma Clin. Cancer Res., December 15, 2005; 11(24): 8606 - 8614. [Abstract] [Full Text] [PDF]

				E. Grafstrom, S. Egyhazi, U. Ringborg, J. Hansson, and A. Platz Biallelic Deletions in INK4 in Cutaneous Melanoma Are Common and Associated with Decreased Survival Clin. Cancer Res., April 15, 2005; 11(8): 2991 - 2997. [Abstract] [Full Text] [PDF]

				M. C.M. Guimaraes, M. A. G. Goncalves, C. P. Soares, J. S.R. Bettini, R. A. Duarte, and E. G. Soares Immunohistochemical Expression of p16INK4a and bcl-2 According to HPV Type and to the Progression of Cervical Squamous Intraepithelial Lesions J. Histochem. Cytochem., April 1, 2005; 53(4): 509 - 516. [Abstract] [Full Text] [PDF]

				Z. Sachs, N. E. Sharpless, R. A. DePinho, and N. Rosenberg p16Ink4a Interferes with Abelson Virus Transformation by Enhancing Apoptosis J. Virol., April 1, 2004; 78(7): 3304 - 3311. [Abstract] [Full Text] [PDF]

				S. R. Alonso, P. Ortiz, M. Pollan, B. Perez-Gomez, L. Sanchez, M. J. Acuna, R. Pajares, F. J. Martinez-Tello, C. M. Hortelano, M. A. Piris, et al. Progression in Cutaneous Malignant Melanoma Is Associated with Distinct Expression Profiles: A Tissue Microarray-Based Study Am. J. Pathol., January 1, 2004; 164(1): 193 - 203. [Abstract] [Full Text] [PDF]

				O. Straume, D. G. Jackson, and L. A. Akslen Independent Prognostic Impact of Lymphatic Vessel Density and Presence of Low-Grade Lymphangiogenesis in Cutaneous Melanoma Clin. Cancer Res., January 1, 2003; 9(1): 250 - 256. [Abstract] [Full Text] [PDF]

				O. Straume, J. Smeds, R. Kumar, K. Hemminki, and L. A. Akslen Significant Impact of Promoter Hypermethylation and the 540 C>T Polymorphism of CDKN2A in Cutaneous Melanoma of the Vertical Growth Phase Am. J. Pathol., July 1, 2002; 161(1): 229 - 237. [Abstract] [Full Text] [PDF]

				O. Straume and L. A. Akslen Importance of Vascular Phenotype by Basic Fibroblast Growth Factor, and Influence of the Angiogenic Factors Basic Fibroblast Growth Factor/Fibroblast Growth Factor Receptor-1 and Ephrin-A1/EphA2 on Melanoma Progression Am. J. Pathol., March 1, 2002; 160(3): 1009 - 1019. [Abstract] [Full Text] [PDF]

				O. Straume and L. A. Akslen Expresson of Vascular Endothelial Growth Factor, Its Receptors (FLT-1, KDR) and TSP-1 Related to Microvessel Density and Patient Outcome in Vertical Growth Phase Melanomas Am. J. Pathol., July 1, 2001; 159(1): 223 - 235. [Abstract] [Full Text] [PDF]

				A. Spatz, G. Giglia-Mari, S. Benhamou, and A. Sarasin Association between DNA Repair-deficiency and High Level of p53 Mutations in Melanoma of Xeroderma Pigmentosum Cancer Res., March 1, 2001; 61(6): 2480 - 2486. [Abstract] [Full Text]